Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Praxis Precision Medicines (Nasdaq: PRAX) granted restricted stock units covering 5,420 shares on May 1, 2026 to 21 new non-executive employees under its 2024 Inducement Plan. Awards were made as inducements under Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest in four equal annual installments, subject to continued employment on each vesting date.
Positive
- None.
Negative
- None.
News Market Reaction – PRAX
In the May 6 session, PRAX gained 1.43%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 14 | NDA accepted | Positive | +8.4% | FDA accepted ulixacaltamide NDA with PDUFA date set for Jan 29, 2027. |
| Apr 13 | Data presentation | Positive | +0.3% | Expanded Phase 3 Essential3 data to be showcased at AAN 2026 meeting. |
| Apr 06 | Clinical results | Positive | -0.1% | Positive EMBRAVE Part A results for elsunersen in pediatric SCN2A DEE. |
| Apr 02 | Inducement grants | Neutral | -0.1% | Inducement RSU awards covering 3,558 shares to new employees under 2024 plan. |
| Mar 30 | NDA priority review | Positive | +16.6% | FDA accepted relutrigine NDA with priority review and PDUFA date set. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and regulatory milestones have often coincided with upward price moves, while routine administrative items like inducement grants have had minimal impact.
Over the past months, Praxis has reported multiple late-stage milestones, including FDA acceptance of NDAs for ulixacaltamide and relutrigine, with moves of 8.39% on Apr 14 and 16.55% on Mar 30. Positive EMBRAVE data for elsunersen on Apr 6 saw little reaction (-0.09%), showing not all clinical wins move the stock. Prior inducement grants on Apr 2 were also low impact. Today’s grants fit the pattern of routine equity awards alongside a broader backdrop of major CNS program progress.
Key Terms
restricted stock unit financial
nasdaq listing rule 5635(c)(4) regulatory
equity awards financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on May 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 5,420 shares of its common stock to twenty-one new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.
About Praxis
Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
Contacts: Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors Daniel@lifesciadvisors.com 617-430-7576